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Highlights 
Unlike SSRI, vortioxetine increases PFC pyramidal activity via blockade of 5-HT3-R 
This effect may be involved in the pro-cognitive action of vortioxetine in rodents 
5-HT3-R blockade may disinhibit 5-HT release by reducing a GABAB tone on 5-HT axons 
Vortioxetine effects are mimicked by escitalopram and ondansetron combinations 
5-HT3-R blockade increases the excitatory/inhibitory balance in PFC and hippocampus 
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ABSTRACT  
 
The antidepressant vortioxetine is a 5-HT3-R, 5-HT7-R and 5-HT1D-R antagonist, 5-HT1B-R partial 
agonist, 5-HT1A-R agonist, and serotonin (5-HT) transporter (SERT) inhibitor. Vortioxetine occupies 
all targets at high therapeutic doses and only SERT and 5-HT3-R at low doses. Vortioxetine 
increases extracellular monoamine concentrations in rat forebrain more than selective serotonin 
reuptake inhibitors (SSRI) and shows pro-cognitive activity in preclinical models. Given its high 
affinity for 5-HT3-R (Ki=3.7 nM), selectively expressed in GABA interneurons, we hypothesized that 
vortioxetine may disinhibit glutamatergic and monoaminergic neurotransmission following 5-HT3-
R blockade.  
Here we assessed vortioxetine effect on pyramidal neuron activity and extracellular 5-HT 
concentration using in vivo extracellular recordings of rat medial prefrontal cortex (mPFC) 
pyramidal neurons and microdialysis in mPFC and ventral hippocampus (vHPC).Vortioxetine, but 
not escitalopram, increased pyramidal neuron discharge in mPFC. This effect was prevented by 
SR57227A (5-HT3-R agonist) and was mimicked by ondansetron (5-HT3-R antagonist) and by 
escitalopram/ondansetron combinations. In microdialysis experiments, ondansetron augmented 
the 5-HT-enhancing effect of escitalopram in mPFC and vHPC. Local ondansetron in vHPC 
augmented escitalopram effect, indicating the participation of intrinsic mechanisms. Since 5-HT 
neurons express GABAB receptors, we examined their putative involvement in controlling 5-HT 
release after 5-HT3-R blockade. Co-perfusion of baclofen (but not muscimol) reversed the 
increased 5-HT levels produced by vortioxetine and escitalopram/ondansetron combinations in 
vHPC. 
The present results suggest that vortioxetine increases glutamatergic  and serotonergic 
neurotransmission in rat forebrain by blocking 5-HT3 receptors in GABA interneurons.  
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1. INTRODUCTION 
Vortioxetine (Lu AA21004) is an antidepressant with a clinical efficacy similar to venlafaxine 
(Alvarez et al., 2012). Vortioxetine inhibits the serotonin (5-HT) transporter (SERT) and shows high 
in vitro affinity for several 5-HT receptors (5-HT-R), including 5-HT3, 5-HT1A, 5-HT1B and 5-HT7 (Mork 
et al., 2012; Sanchez et al., 2015). Vortioxetine has pro-cognitive effects in rodent models (Bétry et 
al., 2015; Sanchez et al., 2015; Wallace et al., 2014) and its administration to rodents increases 
very markedly the extracellular concentration of monoamines in forebrain (Pehrson et al., 2013) to 
an extent greater than that produced by selective serotonin reuptake inhibitors (SSRI). This 
difference is most likely due to the multimodal pharmacological profile of vortioxetine, which may 
prevent local (e.g., mediated by 5-HT1A and 5-HT1B autoreceptors) and distal self-inhibitory 
mechanisms on monoamine cell groups.  
Self-inhibitory mechanisms triggered by 5-HT autoreceptors in response to antidepressant drug 
administration were identified two decades ago (Artigas et al., 1996; Artigas et al. 2001; Piñeyro 
and Blier 1999). In addition to these local mechanisms, distal loops may also modulate 
serotonergic activity. Among them, long distance afferents from the medial prefrontal cortex 
(mPFC) tightly control serotonergic activity (Celada et al., 2001; Hajos et al., 1998;  Martin-Ruiz et 
al., 2001) and play a major role in the response to behavioural challenges (Warden et al., 2012). 
The PFC also projects to the brainstem catecholamine nuclei  (Gabbott et al., 2005) and thus, 
changes in PFC activity may also evoke downstream changes in the activity of the ascending 
dopaminergic and noradrenergic systems. The PFC contains a high density of neurons expressing 
5-HT1A-R (Santana et al., 2004), whose physiological activation inhibits pyramidal neuron activity 
(Amargós-Bosch et al., 2004; Puig et al., 2005). Therefore, 5-HT1A-R activation by vortioxetine 
might modulate pyramidal output to brainstem catecholamine nuclei and increase forebrain 
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catecholamine release, as reported for 5-HT1A-R agonists (Díaz-Mataix et al., 2006; Hajos-Korcsok 
and Sharp 1996). 
In addition, given the high affinity (3.7 nM) of vortioxetine for 5-HT3-R (Mørk et al., 2012), they 
may also participate in the distinctive actions of vortioxetine, compared with SSRIs. 5-HT3-R are 
present in forebrain GABAergic interneurons that control pyramidal neuron activity in 
hippocampus and PFC (Morales and Bloom, 1997; Puig et al., 2004). 5-HT3-R are ion channels and 
their physiological activation by endogenous 5-HT markedly excites mPFC GABA interneurons (Puig 
et al., 2004).  
Using single unit recordings in anesthetized rats, we examined the involvement of 5-HT3-R in the 
mechanism of action of vortioxetine, under the working hypothesis that 5-HT3 receptor blockade 
in GABA interneurons may disinhibit pyramidal neuron activity in mPFC. Likewise, using in vivo 
microdialysis in freely-moving rats, we examined the role of 5-HT3-R blockade as a potential 
negative feed-back mechanism involved in the control of 5-HT release during SERT blockade by 
antidepressant drugs. 
 
2. MATERIAL AND METHODS  
 
2.1 Animals and stereotaxic surgery  
Male albino Wistar rats (Iffa Credo, Lyon, France) weighing 250-340 g were used. Animal care 
followed European Union regulations (directive 2010/63 of September 22, 2010) and was 
approved by the Institutional Animal Care and Use Committee.  
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     2.2 Drugs and treatments 
Vortioxetine (VOR) hydrobromide and escitalopram oxalate (ESCI) were provided by H. Lundbeck 
A/S (Copenhagen-Valby, Denmark). Ondansetron hydrochloride dihydrate (OND, 5-HT3-R 
antagonist), SR57227A (SR, 5-HT3-R agonist), baclofen (BAC, GABAB-R agonist) and muscimol (MUS, 
GABAA-R agonist) were purchased from Sigma-Aldrich (Buchs, Switzerland). Concentrated stock 
solutions were prepared in hydroxyl-propyl-ß-cyclodextrin 30% (VOR), saline (for systemic 
administrations) or artificial cerebrospinal fluid (aCSF, for local perfusions) and aliquots were 
stored at -20°C. Working solutions were prepared daily by dilution. In electrophysiological 
experiments, drugs were administered intravenously (i.v.) through the femoral vein. In 
microdialysis experiments, drugs were administered subcutaneously (s.c.) or locally, by reverse 
microdialysis. The doses used were taken from the literature (Abellán et al., 2000a; 2000b; Bétry 
et al., 2013; Mork et al., 2012; Zhang et al., 2011) or from pilot experiments.  
 
     2.3 Electrophysiological recordings 
Electrophysiological recordings were performed as previously described (Kargieman et al., 2007; 
Puig et al., 2005) typically between 9 am and 3 pm. Rats were anesthetized with chloral hydrate 
(induction: 400 mg/kg i.p.]; maintenance: 50-70 mg/kg/h i.p. using a perfusion pump) to analyze 
the responses of layer V mPFC pyramidal neurons (AP from +3.4 to +3.2; ML from -0.5 to -0.9; DV 
from -1.5 to -4; mm) (Paxinos and Watson, 2005) to the i.v. administration of ESC, VOR, OND and 
SR, alone or in combination. Pyramidal neurons were identified by antidromic stimulation from 
projection areas of the mPFC such as the dorsal raphe ([DR]; AP -7,8;  L -3,1; DV -6.6 electrode 
implanted with an angle of 30o) or the ventral tegmental area ([VTA]; AP -5,8;  L -0,4; DV -8), 
followed by the collision test (Fuller JH and Schlag, 1976). Both stimulation sites identify the same 
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population of midbrain-projecting PFC neurons (Vázquez-Borsetti et al., 2011). DR and VTA were 
stimulated at 0.5–2.0 mA, 0.2 ms square pulses, 0.9 Hz as previously reported (Puig et al., 2005). 
Of the 73 recorded neurons, 62 (85 %) projected to DR, 6 (8 %) projected to VTA and 5 (7 %) 
projected to both areas. Neurons not responding to antidromic activation or without spontaneous 
firing activity were discarded. 
The recording electrodes were filled with saline 2M (impedances 6-12 MΩ). Single unit recordings 
were amplified with a Neurodata IR283 (Cygnus Technology Inc., Delaware Water Gap, PA), post-
amplified and filtered with a Cibertec amplifier (Cibertec, Madrid, Spain) and computed on-line 
using a DAT 1401plus interface system Spike2 software (Cambridge Electronic Design, Cambridge, 
UK).  
Pontamine Sky Blue was added for the identification of the recording site. After obtaining a stable 
baseline recording for 5 min, saline or SR was injected as pre-treatment. After 3-5 min, drugs were 
administered i.v. Cumulative doses were injected every 3 min. Typically, actual recording time was 
23-40 min.  
 
     2.4 In vivo microdialysis 
Microdialysis procedures were conducted as previously described (Amargós-Bosch et al., 2004). 
Briefly, anesthetized rats (sodium pentobarbital, 60 mg/kg i.p.) were stereotaxically implanted 
with concentric microdialysis probes equipped with a 4-mm Cuprophan membrane in the mPFC 
(AP +3.2, ML -0.8, DV –6.0 mm from skull) or ventral hippocampus (vHPC) (AP -5.3, ML -4.8, DV -
8.8 mm from skull). Microdialysis experiments were carried out in freely-moving rats 20-24 h after 
surgery at the same time interval as the electrophysiological experiments. Probes were 
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continuously perfused with aCSF pumped at 1.5 μL/min. Dialysate samples of 30 μL were collected 
every 20 min.  
After an initial 60 min stabilization period, four baseline samples were collected before systemic or 
local pharmacological treatments. In a first set of experiments, ESC and OND were administrated 
both s.c. to study their effect on extracellular 5-HT in mPFC and vHPC. In experiments examining 
the role of hippocampal 5-HT3-R in augmenting the effect of SERT inhibition on extracellular 5-HT, 
ESC or VOR was administered s.c. Once a stable effect was achieved, the perfusion fluid was 
replaced by one containing OND and/or BAC (or MUS). Dialysate 5-HT concentrations were 
analyzed by HPLC-amperometric detection (Hewlett Packard-1049, Palo Alto, CA, USA) at +0.60 V, 
with detection limit of 2 fmol/sample.  
 
     2.5 Histology 
After experimental procedures were completed, animals were euthanized by an anaesthetic 
overdose. The brains were removed, frozen on dry ice and kept at -80°C before being cut into 
coronal sections (50 m) with a cryostat. Brain sections were stained to verify the recording and 
stimulation sites with neutral red or the correct placement of the probes with fast-green. 
 
     2.6 Data and statistical analysis  
Firing rate was quantified by averaging the values in 2-min periods of each experimental period 
(2nd-3rd min after each drug cumulative dose administration or 4th-5th ; 9th-10th; 14th-15th; 19th-20th; 
24th-25th min after a single dose drug injection). Neurons were considered to be excited or 
inhibited when drugs induced a ±30% change of the discharge rate at least in two consecutive 
doses or time periods (Kargieman et al., 2007). 
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Microdialysis data are given as percentage of basal values, averaged from 4 pre-drug fractions and 
also as normalized areas under curve (AUC) corresponding to every treatment period. The 
treatment effects were assessed by one- or two-way repeated measures ANOVA or Student’s t-
test, as appropriate, using Statistica for Windows software (4.5 version) (StatSoft inc.). Post-hoc 
analysis was performed using Duncan’s test. Data are expressed as means ± SEM. Statistical 
significance was set at p<0.05 (two tailed).  
3. RESULTS  
 
     3.1 Vortioxetine effect on mPFC pyramidal activity. Prevention by the 5-HT3-R agonist 
SR57227A  
Vortioxetine (VOR; 0.1-0.2-0.4-0.8-1.6 mg/kg i.v., cumulative doses) dose-dependently increased 
the firing rate in 10 (77%) of the 13 neurons recorded. Two neurons (15%) were unaffected and 
another one (8%) decreased its activity. Maximal effect was observed at 0.4 mg/kg i.v. The 
increased discharge rate persisted for ≥13 min after the last VOR injection. Figure 1A shows a 
representative example of VOR effect on the discharge of an mPFC pyramidal neuron. Figures 1B 
and 1C show the effect of VOR in all neurons (231±44% of baseline, n=13) and in activated neurons 
(273±51% of baseline, n=10). One-way ANOVA revealed a significant effect of VOR when 
considering all neurons (F(6,72)=3.00; p<0.02, n=13) or only excited neurons (F(6,54)=3.21; p<0.01, 
n=10) and post-hoc differences between VOR (0.4-0.8-1.6 mg/kg i.v.) and baseline-saline values.  
Given the high affinity of VOR for 5-HT3-R, we studied the potential prevention of its effect by the 
5-HT3-R agonist SR57227A by comparing SR57227A+VOR versus SAL+VOR. A single dose (1.28 
mg/kg i.v.) of SR57227A fully prevented the elevation of pyramidal cell firing induced by VOR. Two‐
way ANOVA revealed significant effects of pre‐treatment (F(1,22)=4.41; p<0.05), treatment 
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(F(6,132)=4.03; p<0.002) and pre-treatment·treatment interaction (F(6,132)=2.83; p<0.02 n=13 
and 11 for SAL+VOR, and SR57227A+VOR groups, respectively), with significant post‐hoc 
differences between SAL and SR57227A pre‐treatments at VOR doses of 0.4, 0.8 and 1.6 mg/kg i.v. 
Figure 1D shows a representative example of the lack of an effect of cumulative doses of VOR in 
SR57227A‐pre-treated rats. Figure 1E shows the prevention by SR57227A of VOR effect in all 
neurons. The prevention of VOR effect by SR57227A was observed in 10 of the 11 pyramidal 
neurons. Figure 1F shows the dose‐effect relationships for both experimental groups. 
 
     3.2 Effect of ESC, OND and ESC+OND on pyramidal neuron activity in mPFC 
The administration of escitalopram (ESC, 0.1-0.2-0.4-0.8-1.6 mg/kg i.v., cumulative doses) did not 
alter the discharge rate of mPFC pyramidal neurons (n=9). Five neurons (55.5%) were not 
significantly activated, 3 were unaffected (33.3%) and 1 was inhibited (11.2%). Figures 2A and 2B 
show a representative example and the effect of ESC in all recorded neurons, respectively. 
Similarly, a single dose of ESC (0.1 mg/kg i.v.) did not affect the firing rate of mPFC pyramidal 
neurons (n=8). Five neurons (62.5%) were not significantly inhibited by ESC,  1 (12.5%) was 
unaffected and 2 (25%) were not significanty activated. Figure 2C shows the effect of a single dose 
of ESC in all recorded neurons. 
The administration of ondansetron (OND; 0.16-0.32-1.28 mg/kg i.v., cumulative doses) evoked a 
dose-dependent increase in pyramidal discharge in 7 out of 11 neurons (63.6%) recorded (4 were 
unaffected; 36.4%). The maximal effect was achieved at 1.28 mg/kg i.v. Figure 2D shows a 
representative example of an activated neuron. Figures 2E and 2F show the effect of OND in all 
neurons (239±55% of baseline, n=11) and in activated neurons (311±74% of baseline, n=7). One-
way ANOVA revealed a significant effect of OND when considering all neurons (F(4,40)=2.91; 
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p<0.05, n= 11) or only excited neurons (F(4,24)=3.31; p<0.03, n= 7) with post-hoc differences 
between OND (1.28 mg/kg i.v.) and baseline-saline values. The increased discharge rate persisted 
for ≥20 min after the last OND injection. Similarly, a single dose of OND (1.28 mg/kg i.v.) increased 
the firing rate in 6 of the 9 (66.7%) pyramidal neurons recorded. Two neurons (22.2%) were 
inhibited and 1 (11.1%) was unaffected. Maximal effect was observed at 10 min post-
administration and persisted for the duration of recordings (typically 25 min post-administration). 
Figure 2 shows representative examples of activated (2G) and unaffected (2H) neurons. Figure 2I 
shows the effect of OND in all neurons (253±73% of baseline, n=9) and in the subgroup of excited 
neurons (333±94% of baseline, n=6). One-way ANOVA indicated a significant effect of the 
treatment for all neurons (F(6,48)=2.28; p<0.03; n=9) or only excited neurons (F(6,30)=4.18; 
p<0.005; n=6), with post-hoc differences between OND (1.28 mg/kg i.v. at 10-15-20-25 min after 
administration) and baseline-saline values.  
In order to further clarify the role of 5-HT3-R in the enhancing effect on pyramidal activity by VOR, 
we evaluated the action of ESC+OND (to mimic the mechanism of action of VOR). This drug 
combination evoked an increase in the firing rate in 9 out of 12 (75%) recorded neurons. Three 
neurons (25%) were unaffected. The combination of OND+ESC increased pyramidal neuron 
discharge to an extent similar to OND alone. Maximal effect was observed at 10 min post-
administration and persisted for the duration of recordings (25 min post-administration). Figure 2J 
shows a representative example of an activated neuron. Figure 2K shows the effect of the drug 
combination in all neurons (290±52% of baseline, n=12) and in the subgroup of excited neurons 
(357±53% of baseline, n=9). One-way ANOVA indicated a significant effect of treatment 
considering all neurons (F(6,66)=5.88; p<0.0001; n=12) or only excited neurons (F(6,48)=7.41; 
p<0.00001; n=9), with post-hoc differences between ESC+OND at 5-10-15-20-25 min post-
administration and baseline-saline values.  
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Finally, we compared the effects on the mPFC pyramidal discharge induced by the three 
treatments (ESC, OND, ESC+OND). Two-way ANOVA (with time and treatment as factors) revealed 
a significant effect of time (F(6,156)=7.73; p<0.00001), treatment (F(2,26)=3.53; p<0.05) and 
treatment x time interaction (F(12,156)=1.90; p<0.05) (n=8, 9 and 12 for ESC, OND and ESC+OND 
groups, respectively), with post-hoc differences between OND or ESC+OND and ESC (Fig. 2L).  
 
     3.3 Effect of systemic administration of ESC and OND on extracellular 5-HT concentration in 
mPFC and vHPC. 
OND administration (10 mg/kg s.c.) had no effect alone but augmented the effect of ESC (3.2 
mg/kg s.c.) on extracellular 5‐HT in mPFC (Figures 3A-3B) and vHPC (Figures 3C-3D). In mPFC, two‐
way ANOVA for repeated measures of AUC values revealed significant effects of group 
(F(3,25)=11.38; p<0.00001), treatment (F(2,50)=17.01; p<0.00001) and treatment·group 
interaction (F(6,50)=8.69; p<0.00001, n=4, 6, 10 and 9  for SAL+SAL, SAL+OND, ESC+SAL and 
ESC+OND groups, respectively) with significant post‐hoc differences between ESC+OND and ESC. In 
vHPC, two‐way ANOVA for repeated measures of AUC values also revealed significant effects of 
group (F(3,27)=10.76; p<0.0001), treatment (F(2,54)=11.26; p<0.0001) and treatment·group 
interaction (F(6,54)=9.10; p<0.00001, n=5, 5, 9 and 12 for SAL+SAL, SAL+OND, ESC+SAL and 
ESC+OND groups, respectively) with significant post‐hoc differences between ESC+OND and ESC. 
 
     3.4 Relevance of local 5-HT3-R in vHPC on vortioxetine effect on extracellular 5-HT: 
involvement of GABAB-R. 
To examine the potential involvement of local 5‐HT3-R –containing microcircuits in vHPC in the 
augmentation of ESC effects by systemic OND, we examined the ability of local OND infusion in 
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vHPC (300 μM in aCSF) to augment the effect of ESC (3.2 mg/kg s.c.) on extracellular 5‐HT (Figures 
4A and 4B). The s.c. ESC administration increased extracellular 5‐HT in vHPC to ≈3‐fold the basal 
levels. This effect was sustained, lasting for ≈15 fractions (300 min). The local application of 300 
μM OND in vHPC produced a robust potentiation of ESC effect. Two‐way ANOVA for repeated 
measures of AUC values revealed significant effects of group (F(1,12)=7.75; p<0.02), treatment 
(F(2,24)=42.13; p<0.00001) and treatment·group interaction (F(2,24)=9.97; p<0.001 n=7 for both 
ESC and ESC+OND groups), with significant post‐hoc differences between ESC and ESC+OND. Local 
OND application alone increased the extracellular 5‐HT concentration in vHPC (380±8% of basal 
values; p<0.03; n=5) (Figure 4C).  
Unlike mPFC, the vHPC lacks afferent pathways to the raphe nuclei that may explain the OND 
augmentation of ESC effect, thus suggesting the involvement of local microcircuits in this effect. 
We then hypothesized that 5-HT3-R blockade by OND and VOR would reduce GABA release and 
consequently, the GABA tone on local GABAB-R controlling 5‐HT release. We then examined 
whether the restoration of the GABAB-R tone with baclofen (BAC) could attenuate the augmenting 
effect of OND on extracellular 5‐HT. The local co‐perfusion of BAC (100 μM) by reverse dialysis in 
vHPC fully reversed the increase of extracellular 5‐HT produced by the local application of OND 
after systemic ESC administration, and normalised 5‐HT values (Figures 4D and 4E). One-way 
ANOVA for repeated measures of AUC values revealed significant effect of treatment 
(F(3,15)=10.79; p<0.0005; n=6), with significant post‐hoc differences between ESC, ESC+OND and 
ESC+OND+BAC treatments. Moreover, the local perfusion of BAC did not alter ESC‐induced 
increase of extracellular 5‐HT (Figure 4F). One‐way ANOVA for repeated measures of AUC values 
revealed significant effect of treatment (F(2,10)=4.77; p<0.05; n=6), with no post‐hoc differences 
between ESC and ESC+BAC treatments. 
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Similarly, local BAC infusion (100 μM in aCSF) by reverse dialysis in vHPC attenuated the effect of 
VOR (5 mg/kg s.c.) on extracellular 5‐HT. Unlike BAC, local administration of the GABAA-R agonist 
muscimol (MUS) in vHPC (100 μM in aCSF) failed in reversing VOR effect on extracellular 5‐HT. 
(Figures 4G and 4H). Two‐way ANOVA for repeated measures of AUC values revealed significant 
effects of group (F(2,18)=9.15; p<0.002), treatment (F(2,36)=53.29; p<0.00001) and the 
treatment·group interaction (F(4,36)=14.72; p<0.00001 n=9, n=7 and n=5 for VOR, VOR+BAC and 
VOR+MUS, respectively) with significant post‐hoc differences between VOR or VOR+MUS and 
VOR+BAC treatments.  
 
4. DISCUSSION 
 
The present results indicate that acute vortioxetine administration dose-dependently increased 
the discharge rate of mPFC pyramidal neurons projecting to midbrain, with a maximal effect at 0.4 
mg/kg i.v. In contrast, escitalopram did not significantly alter the same neuronal population at 
doses that fully block SERT (vortioxetine: Bétry et al., 2013, escitalopram: unpublished 
observations). Likewise, vortioxetine increased extracellular 5-HT concentration in mPFC and vHPC 
to an extent greater than that evoked by escitalopram. This difference is likely due to the 
simultaneous blockade of SERT and 5-HT3-R by vortioxetine, since its effects were prevented by 
the 5-HT3-R agonist SR57227A and were mimicked by escitalopram and ondansetron combinations 
(and by ondansetron alone for pyramidal discharge elevations).  
We suggest that vortioxetine blockade of 5-HT3-R disinhibits pyramidal neuron activity and 5-HT 
release following the removal of the GABAergic tone on pyramidal neurons (mainly mediated by 
GABAA-R) and on 5-HT nerve terminals (mediated by GABAB-R) (Figure 5). Hence, unlike SSRI, 
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vortioxetine increased the glutamatergic/GABAergic neurotransmission ratio in rat brain. These 
effects may explain the superior effects of vortioxetine in various experimental models, such as 
neurotransmitter release (Pehrson et al., 2013) and pro-cognitive effects in rodents (Bétry et al., 
2015; Sanchez et al., 2015; Wallace et al., 2014). 
5-HT3-Rs are exclusively expressed in GABAergic interneurons in cortical and hippocampal areas 
(Lee at al., 2010; Morales and Bloom, 1997; Puig et al., 2004). 5-HT3-R have also been identified in 
GABAergic interstitial cells of the corpus callosum, which may control cortical and subcortical 
networks (von Engelhardt et al., 2011). Cortical GABAergic interneurons activate GABAA-R to 
rapidly control electrical and biochemical signalling in pyramidal neurons. GABAergic interneurons 
are classified according to their morphology, connectivity, electrophysiological properties and 
expression profile of neuropeptides and calcium binding proteins, such as parvalbumin (PV), 
calbindin or calretinin (DeFelipe et al., 2013). PV-positive neurons are a subpopulation of 
GABAergic cells comprising chandelier and large basket cells (DeFelipe, 1997) that tightly control 
neuronal activity via axo-somatic (basket cells) or axo-axonic (chandelier cells) synapses on deep 
layer pyramidal neurons (DeFelipe and Fariñas, 1992). In the mPFC, 5-HT3-R are expressed in non-
PV, non-somatostatin GABAergic interneurons, which are located in upper cortical layers (Lee at 
al., 2010; Morales and Bloom, 1997; Puig et al., 2004), which include neurogliaform cells (Oláh et 
al., 2009; Tamás et al., 2003) and VIP-expressing interneurons (Lee et al., 2013; Pi et al., 2013). The 
percentage of mPFC GABAergic neurons expressing 5-HT3-R is 40% in layer I, 18 % in layers II-III, 6% 
in layer V and 8% in layer VI (Puig et al., 2004). Given their predominant location in superficial 
layers, we expected that 5-HT3-R blockade would have a moderate impact on the activity of 
midbrain-projecting pyramidal neurons, located in layers V-VI (Gabbott et al., 2005). However, 
≈70% of the recorded pyramidal neurons showed a marked increase of their discharge rate after 
5-HT3-R blockade with vortioxetine or ondansetron.  
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Several reasons may account for this apparent discrepancy. On the one hand, 5-HT3-R are ion 
channels and their physiological stimulation by 5-HT markedly increased the discharge of 5-HT3-R-
expressing GABAergic interneurons in mPFC (Puig et al., 2004). In agreement, the 
microiontophoretic and systemic administration of 5-HT3-R agonists decreased the firing activity of 
putative pyramidal neurons in mPFC (Ashby et al., 1991; Bachy et al., 1993; Edwards et al., 1996). 
Similar effects have been reported in the hippocampus after the physiological release of 5-HT or 
local application of 5-HT3-R agonists (Varga et al., 2009).  Hence, 5-HT3-R-expressing interneurons 
may inhibit pyramidal activity more than anticipated from their location in superficial and middle 
layers due to the ionic nature of 5-HT3-R.  On the other hand, 5-HT3-R may be present in GABAergic 
interneurons controlling pyramidal neuron activity via axo-somatic contacts (Freund 2003; Marlin 
and Carter, 2014) and/or in cortical networks of synaptically- and electrically-coupled interneurons 
(Galarreta and  Hestrin, 2001; Tamás et al., 2003; Traub et al., 2001).  
Overall, the present results are consistent with a strong and rapid ionotropic action of 5-HT on a 
subpopulation of cortical and hippocampal interneurons through the activation of 5-HT3-R. The 
present observations suggest that 5-HT3-R are tonically activated by 5-HT in the anaesthetized rat 
since both vortioxetine and ondansetron elevated pyramidal neuron discharge. Given the 
presence of an excitatory control of the mPFC on 5-HT neuronal activity (Celada et al., 2001; Hajos 
et al., 1998), it is likely that the actions of vortioxetine in mPFC may contribute to the rapid 
recovery of serotonergic cell firing observed after repeated vortioxetine treatment (Bétry et al., 
2013;  Sanchez et al., 2015). 
The increased pyramidal discharge induced by vortioxetine in mPFC may also be involved in its 
pro-cognitive effect in rodents (Bétry et al., 2015; Sanchez et al., 2015; Wallace et al., 2014). The 
PFC is critically involved in cognition, including working memory and executive functions (Miller 
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and Cohen, 2001). Primate studies have revealed that the neurobiological substrate of working 
memory is the maintenance of patterns of persistent neuronal activity in the dorsolateral PFC 
(equivalent to the prelimbic mPFC in rodents) during mnemonic processes (Curtis and D'Esposito, 
2003; Fuster and  Alexander, 1971). Hence, the increased pyramidal discharge induced by 
vortioxetine may facilitate the emergence and maintenance of these activity patterns during 
working memory tasks.  
Another distinctive feature of vortioxetine is its ability to increase extracellular monoamine 
concentrations above the level produced by SSRI (Pehrson et al., 2013). Here we provide evidence 
that, at least for 5-HT, this effect is likely due to the removal of a GABAB-R tone on 5-HT terminals 
following 5-HT3-R blockade in local interneurons. Ondansetron augmented the effect of 
escitalopram on extracellular 5-HT in mPFC and vHPC, indicating that 5-HT3-R blockade can 
facilitate 5-HT release following SERT inhibition in both areas. Further experiments were carried 
out in vHPC, which -unlike mPFC- lacks direct afferent pathways to midbrain raphe, thus avoiding 
potential confounding effects due to the distal modulation of serotonergic neuron activity. Local 
ondansetron application in vHPC also augmented escitalopram effect on extracellular 5-HT, 
suggesting the existence of local microcircuits that attenuate 5-HT release via 5-HT3-R activation. 
Raphe 5-HT neurons express GABAB-R (Abellán et al., 2000a), which exert a biphasic control of 5-
HT neuronal activity and 5-HT release (Abellán et al., 2000b; Tao et al., 1996;). In control 
conditions, stimulation of terminal GABAB-R did not affect striatal 5-HT release (Abellán et al., 
2000), possibly due to the existence of a tonic control by endogenous GABA. However, the present 
results suggest that the removal of the GABA tone on hippocampal GABAB-R disinhibits 5-HT 
release, and that the restoration of the tone by the prototypical GABAB-R  agonist baclofen -but 
not the GABAA-R agonist muscimol- attenuates 5-HT release (see Figure 4H).  
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5. CONCLUSIONS 
 
In summary, the present study indicates that vortioxetine has strong antagonist effects on 5-HT3-R 
which add on top of SERT inhibition to evoke a robust disinhibition of pyramidal neuron activity in 
mPFC and of 5-HT release in forebrain. Since vortioxetine shows affinity for various 5-HT-R, an 
additional role of other receptors (e.g., 5-HT1A-R, 5-HT1B-R, 5-HT7-R) cannot be discarded. However, 
it is likely that the simultaneous blockade of SERT and 5-HT3-R accounts for the differential actions 
of vortioxetine in rodents, compared to SSRIs, such as the greater increase in extracellular 
monoamine concentrations and the pro-cognitive actions. The present results also show that, in 
addition to 5-HT1A and 5-HT1B autoreceptors, forebrain serotonergic activity is tonically limited by 
the activation of 5-HT3-R in GABAergic interneurons. The latter inhibitory effect can be exerted at 
the local level (e.g., by negatively modulating 5-HT release) or distally, via the attenuation of 
mPFC-midbrain excitatory pathways after the stimulation of 5-HT3-R in GABAergic interneurons. 
The attenuation of these negative feed-mechanisms may improve serotonergic activity and 
therefore, the treatment of major depression.  
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FIGURE LEGENDS  
 
 
Figure 1. Effect of vortioxetine (VOR) on the firing rate of layer V (midbrain-projecting) pyramidal neurons 
in rat medial prefrontal cortex (mPFC) and its prevention by the 5-HT3-R agonist SR57227A (SR). A) 
Representative example of a pyramidal neuron whose discharge was increased by intravenous VOR 
administration (0.1-0.2-0.4-0.8-1.6 mg/kg i.v., cumulative doses). B) and C) Bar graphs showing the average 
effect of VOR on firing rate in all neurons (B, n=13) and in the subpopulation of excited neurons (C, n=10). D) 
Representative example of the prevention of VOR effect on mPFC pyramidal discharge by pre-treatment 
with SR57227A (1.28 mg/kg, i.v.). Note the lack of effect of the 5-HT3-R agonist SR57227A on pyramidal 
discharge. E) Bar graph showing the lack of VOR effect in SR57227A pre-treated rats in all recorded neurons 
(n=11). F) Graph showing the comparison between saline (SAL) + vortioxetine (SAL+VOR) and SR57227A + 
vortioxetine (SR+VOR) groups. *p<0.05 versus basal (BAS) and SAL values in SAL+VOR group; #p<0.003 SAL 
versus SR57227A pre-treatments at VOR doses of 0.4, 0.8 and 1.6 mg/kg i.v. 
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Figure 2. Effects of escitalopram (ESC, a selective serotonin reuptake inhibitor, SSRI), ondansetron (OND, a 
5-HT3-R antagonist) and the combination of escitalopram + ondansetron (ESC+OND) on pyramidal neuron 
activity in mPFC. A) Example of a pyramidal neuron whose discharge was unaffected by ESC cumulative 
doses administration (0.1-0.2-0.4-0.8-1.6 mg/kg i.v.). B) Bar graph showing the average effect of ESC on 
firing rate in all neurons (n=9). C) Graph showing the lack of effect of the administration of a single dose of 
ESC (0.1 mg/kg i.v., n=8) during a 25-min period after drug administration. D) Example of a pyramidal neuron 
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whose discharge was augmented by OND cumulative doses administration (0.32-0.64-1.28 mg/kg i.v.). E) 
and F) Bar graphs showing the average effect of OND on firing rate in all neurons (E, n=11) and in excited 
neuron subpopulation (F, n=7). G) and H) Examples of two pyramidal neurons showing an increase G) or a 
lack of effect H) after OND administration (1.28 mg/kg i.v., single dose). I) Graph showing the increasing 
effect on pyramidal activity of single dose of OND in all neurons (n=9) and in excited neuron subpopulation 
(n=6). J) Representative example of a pyramidal neuron response to the administration of the drug 
combination ESC (0.1 mg/kg i.v.) + OND (1.28 mg/kg i.v.). K) Graph showing the increasing effect of a single 
dose of OND on pyramidal activity in all neurons (n=9) and in excited neuron subpopulation (n=6). L) Graph 
showing the comparison between escitalopram (ESC), ondansetron (OND) and escitalopram + ondansetron 
(ESC+OND) groups. *p<0.05 vs Basal and SAL values in OND (single and cumulative doses) and ESC+OND 
groups; #p<0.05 ESC at 10’-15’-20’-25’ min after administration versus OND (10-15-20-25 min after 
administration) and ESC+OND (5-10-15-20-25 min after administration). 
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Figure 3. Effect of systemic administration of escitalopram (ESC) and ondansetron (OND) on extracellular 5-
HT concentration in medial prefrontal cortex (mPFC) and ventral hippocampus (vHPC). The subcutaneous 
(10 mg/kg) administration of OND augments the enhancing effect of ESC (3.2 mg/kg s.c.) on extracellular 5-
HT in mPFC (A and B) and vHPC (C and D). Note the lack of effect of OND by itself in both areas. A) and C) 
Graphs show data as % of basal values averaged from 4 pre-drug fractions during two 120-min post-drug 
administration periods in mPFC (A) and vHPC (C). B) and D) Results are also represented as normalized areas 
under curve (AUC) corresponding to each treatment period for mPFC B) and vHPC C). The experimental 
groups performed for each area are: escitalopram + ondansetron (ESC+OND), escitalopram + saline 
(ESC+SAL), saline + ondansetron (SAL+OND) and saline + saline (SAL+SAL). Arrows mark first and second drug 
administrations. * p<0.01 versus Basal values; # p<0.05 versus ESC in ESC+OND group; α p<0.0001 ESC+OND 
versus ESC+SAL periods.  
 
  Riga MS et al 
33 
 
Figure 4. Relevance of local hippocampal microcircuits containing 5-HT3-R in vortioxetine effect on 
extracellular 5-HT. Involvement of GABAB-R. A) and B) Graphs (A % of basal values; B AUCs) showing the 
potentiating effect of local infusion in vHPC of the 5-HT3-R antagonist ondansetron (OND, 300 µM) on the 
augmenting in extracellular 5-HT concentration induced by systemic administration of escitalopram (ESC, 3.2 
mg/kg s.c.) in freely-moving rats. Note that the local administration of OND alone increases the extracellular 
5-HT concentration in vHPC (C). D) and E) The local co‐perfusion of baclofen (BAC, 100 μM) by reverse 
dialysis in vHPC reverses the increase of extracellular 5‐HT produced by the local application of OND after 
systemic ESC administration. Data are represented as % of basal values (D) or as AUC.(E). Note that the local 
administration of BAC alone does not alter the effect induced by the systemic administration of ESC (F). G) 
(% of basal values) and H) (AUCs) Local BAC infusion (100 μM in aCSF) in vHPC (but not muscimol, MUS, 100 
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μM in aCSF) attenuates the effect of systemic VOR (5 mg/kg s.c.) on extracellular 5‐HT levels. * p<0.05 vs 
Basal values; # p<0.03 ESC versus ESC+OND; α p<0.03 ESC+OND versus ESC+OND+BAC; β p<0.0001 VOR+BAC 
versus VOR and VOR+MUS.  
 
Figure 5. Schematic representation of the putative actions of vortioxetine on pyramidal neuron discharge 
and on 5-HT release. The blockade of 5-HT3-R located on GABA interneurons reduces GABA input onto 
GABAA-R controlling the activity of mPFC pyramidal neurons, thus enhancing their discharge rate. Likewise, 
blockade of 5-HT3-R reduces the GABA tone on terminal GABAB-R controlling 5-HT release by nerve 
terminals, therefore augmenting the effect of SERT blockade on extracellular 5-HT (see text for an extended 
discussion). 
